LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Simultaneous glucose and xylose utilization by an

    Kaplan, Nicholas A / Islam, Khondokar Nowshin / Kanis, Fiona C / Verderber, Jack R / Wang, Xin / Jones, J Andrew / Koffas, Mattheos A G

    Applied and environmental microbiology

    2024  Volume 90, Issue 2, Page(s) e0216923

    Abstract: As advances are made toward the industrial feasibility of mass-producing biofuels and commodity chemicals with sugar-fermenting microbes, high feedstock costs continue to inhibit commercial application. Hydrolyzed lignocellulosic biomass represents an ... ...

    Abstract As advances are made toward the industrial feasibility of mass-producing biofuels and commodity chemicals with sugar-fermenting microbes, high feedstock costs continue to inhibit commercial application. Hydrolyzed lignocellulosic biomass represents an ideal feedstock for these purposes as it is cheap and prevalent. However, many microbes, including
    MeSH term(s) Escherichia coli/genetics ; Escherichia coli/metabolism ; Glucose/metabolism ; Xylose/metabolism ; Catabolite Repression ; Cyclic AMP Receptor Protein/genetics ; Cyclic AMP Receptor Protein/metabolism ; Sugars/metabolism ; Fermentation ; Carbon/metabolism
    Chemical Substances Glucose (IY9XDZ35W2) ; Xylose (A1TA934AKO) ; Cyclic AMP Receptor Protein ; Sugars ; Carbon (7440-44-0)
    Language English
    Publishing date 2024-01-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 223011-2
    ISSN 1098-5336 ; 0099-2240
    ISSN (online) 1098-5336
    ISSN 0099-2240
    DOI 10.1128/aem.02169-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 201: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: In vivo production of psilocybin in E. coli.

    Adams, Alexandra M / Kaplan, Nicholas A / Wei, Zhangyue / Brinton, John D / Monnier, Chantal S / Enacopol, Alexis L / Ramelot, Theresa A / Jones, J Andrew

    Metabolic engineering

    2019  Volume 56, Page(s) 111–119

    Abstract: Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. The development of a psilocybin production platform in a ... ...

    Abstract Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. The development of a psilocybin production platform in a highly engineerable microbe could lead to rapid advances towards the bioproduction of psilocybin for use in ongoing clinical trials. Here, we present the development of a modular biosynthetic production platform in the model microbe, Escherichia coli. Efforts to optimize and improve pathway performance using multiple genetic optimization techniques were evaluated, resulting in a 32-fold improvement in psilocybin titer. Further enhancements to this genetically superior strain were achieved through fermentation optimization, ultimately resulting in a fed-batch fermentation study, with a production titer of 1.16 g/L of psilocybin. This is the highest psilocybin titer achieved to date from a recombinant organism and a significant step towards demonstrating the feasibility of industrial production of biologically-derived psilocybin.
    MeSH term(s) Batch Cell Culture Techniques ; Escherichia coli/genetics ; Escherichia coli/growth & development ; Metabolic Engineering ; Psilocybin/biosynthesis ; Psilocybin/genetics
    Chemical Substances Psilocybin (2RV7212BP0)
    Language English
    Publishing date 2019-09-21
    Publishing country Belgium
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1470383-x
    ISSN 1096-7184 ; 1096-7176
    ISSN (online) 1096-7184
    ISSN 1096-7176
    DOI 10.1016/j.ymben.2019.09.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6288: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: In vivo production of psilocybin in E. coli

    Adams, Alexandra M / Kaplan, Nicholas A / Wei, Zhangyue / Brinton, John D / Monnier, Chantal S / Enacopol, Alexis L / Ramelot, Theresa A / Jones, J. Andrew

    International Metabolic Engineering Society Metabolic engineering. 2019 Dec., v. 56

    2019  

    Abstract: Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. The development of a psilocybin production platform in a ... ...

    Abstract Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. The development of a psilocybin production platform in a highly engineerable microbe could lead to rapid advances towards the bioproduction of psilocybin for use in ongoing clinical trials. Here, we present the development of a modular biosynthetic production platform in the model microbe, Escherichia coli. Efforts to optimize and improve pathway performance using multiple genetic optimization techniques were evaluated, resulting in a 32-fold improvement in psilocybin titer. Further enhancements to this genetically superior strain were achieved through fermentation optimization, ultimately resulting in a fed-batch fermentation study, with a production titer of 1.16 g/L of psilocybin. This is the highest psilocybin titer achieved to date from a recombinant organism and a significant step towards demonstrating the feasibility of industrial production of biologically-derived psilocybin.
    Keywords Escherichia coli ; batch fermentation ; biosynthesis ; clinical trials
    Language English
    Dates of publication 2019-12
    Size p. 111-119.
    Publishing place Elsevier Inc.
    Document type Article
    ZDB-ID 1470383-x
    ISSN 1096-7184 ; 1096-7176
    ISSN (online) 1096-7184
    ISSN 1096-7176
    DOI 10.1016/j.ymben.2019.09.009
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6288: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top